Pharma channel feed – Endpoints News

Pharma channel feed

Celgene, Agios beat a short path to an FDA decision on AML drug

9 years ago

The top 10 orphan drugs in the late-stage pipeline

9 years ago

Trump attacks “slow and burdensome” drug approval process, triggering a pitch from Amicus CEO

9 years ago

Lexicon bags FDA OK on lead drug for carcinoid syndrome, preps for a commercial launch

9 years ago

Cempra slashes staff while shares tank (again) after a new series of setbacks for lead antibiotic

9 years ago

Gates-backed Affinivax grabs $10M upfront and a major league partner for a groundbreaking attempt to beat Pfizer’s superstar vaccine

9 years ago

Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna

9 years ago

With hep C franchises languishing, Merck’s MK-3682 goes from blockbuster to bomb

9 years ago

Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction

9 years ago

The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up

9 years ago

Big Pharma CEOs push hard for tax reform and a proposed border levy

9 years ago

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

9 years ago

Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review

9 years ago

Gilead bags Sarepta's priority review voucher for a discount, paying $125M

9 years ago

An FDA reform agenda: What would Commissioner Scott Gottlieb do in his first six months?

9 years ago

After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar’s intranasal version

9 years ago

Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well

9 years ago

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

9 years ago

Alexion shelves an early-stage Sanfilippo B drug, writes off $85M

9 years ago

PhRMA disses Marathon CEO—and PhRMA board member—Jeff Aronin after latest price gouging controversy

9 years ago

Valeant gets an FDA OK for new psoriasis drug brodalumab — but there’s a big catch

9 years ago

Patent board tells CRISPR scientists to back off from a nasty fight over gene editing tech

9 years ago

The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump

9 years ago

Agenus pockets a fast $80M in cash and hands the R&D keys over to Incyte

9 years ago

First page Previous page 335 336 337338339 340 341 Next page Last page